LEAP2 is associated with cardiometabolic markers but is unchanged by antidiabetic treatment in people with prediabetes
Sarah Byberg, Martin Bæk Blond, Stephanie Holm, Hanan Amadid, Lea Bruhn, Kim Katrine Bjerring Clemmensen, Kristine Færch, Birgitte Holst
Abstract
LEAP2, primarily secreted by the liver, increases with greater body mass, insulin resistance, and liver-specific enzymes in individuals with prediabetes and overweight or obesity. Fasting glucose, body mass, and alanine aminotransferase independently predict LEAP2 levels. LEAP2 is inversely linked to impaired kidney function. Elevated LEAP2 levels might indicate an increased metabolic risk, warranting further investigation into its potential involvement in glucose and body weight control.
Topics & Concepts
Internal medicinePrediabetesMedicineBody mass indexEndocrinologyMetforminOverweightObesityInsulinCohortDiabetes mellitusType 2 diabetesLiver Disease Diagnosis and TreatmentRegulation of Appetite and ObesityDiabetes Treatment and Management